Trial Profile
Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2014
Price :
$35
*
At a glance
- Drugs NXN 188 (Primary)
- Indications Migraine without aura
- Focus Therapeutic Use
- Sponsors NeurAxon
- 01 Nov 2010 Primary endpoint 'Headache severity' has not been met.
- 01 Nov 2010 Results were reported in a NeuAxon media release.
- 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.